Importantly, Bailur et al. demonstrated that the ability of women with HER2+ breast cancer to mount an immune response against the HER2 antigen was linked with low levels of Lin−CD14+HLA-DR− MDSCs and Treg cells, and that this was associated with a 100% 5-year survival rate compared to only 38% for those who had no detectable level of Her2-reactive CD8+ T cells, but had high frequencies of MDSCs (27). This evidence concerns the gene ERBB2 and breast cancer.